Zhengye Biotechnology Holding (ZYBT) Notes Payables (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Notes Payables for 3 consecutive years, with $9.2 million the latest figure, recorded in Q4 2025.

• Quarterly Notes Payables fell 11.43% year-over-year to $9.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.2 million (down 11.43% YoY) and the FY2025 annual result came in at $9.3 million, down 8.73% from the prior year.
• Notes Payables fell to $9.2 million in Q4 2025 per ZYBT's latest filing, from $11.3 million in the prior quarter.
• Over the last five years, Notes Payables for ZYBT reached as high as $11.3 million in Q2 2025 and fell as low as $9.2 million in Q4 2025.
• A 3-year average of $10.5 million and a median of $10.7 million in 2023 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2024 — Notes Payables dropped 6.56% — and 2025, when it decreased 11.43%.
• Year by year, Notes Payables stood at $11.1 million in 2023, then dropped by 6.56% to $10.4 million in 2024, then slipped by 11.43% to $9.2 million in 2025.
• According to Business Quant data, Notes Payables over the past three periods registered $9.2 million, $11.3 million, and $10.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.